N,N-diethyl-4-n-propylbenzamide | 850035-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl-4-n-propylbenzamide
• 英文别名: N,N-diethyl-4-propylbenzamide
• CAS: 850035-53-9
• 化学式: C₁₄H₂₁NO
• mdl: MFCD27979180
• 分子量: 219.327
• InChiKey: KBXIHGYHDGTQGE-UHFFFAOYSA-N

物化性质

• 沸点：
  346.2±21.0 °C(Predicted)
• 密度：
  0.965±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-4-n-propylbenzamide 在 四甲基乙二胺 、 (2-methylpropyl)lithium 、 硼酸三甲酯 、 盐酸 、 氯化铵 作用下， 以 四氢呋喃 、 环己烷 为溶剂， 反应 2.0h， 生成 2-diethyl-carbamoyl-5-propylphenylboronic acid
  参考文献：
  名称：

  JP2005/350455

  摘要：

  公开号：
• 作为产物：
  描述：

  4-丙基苯甲酰氯 、 二乙胺 生成 N,N-diethyl-4-n-propylbenzamide
  参考文献：
  名称：

  JP2005/350455

  摘要：

  公开号：

文献信息

• Modulators of serotonin receptors
  申请人：Wacker A. Dean

  公开号：US20050080074A1

  公开（公告）日：2005-04-14

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了血清素受体调节剂，包含这些调节剂的药物组合物以及治疗与血清素受体调节相关的各种疾病、症状和疾患的方法，例如：代谢性疾病，包括但不限于肥胖、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、恐慌症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Polyfluorinated fused aromatics and their use in liquid-crystal mixtures
  申请人：Schmidt Wolfgang

  公开号：US20050255258A1

  公开（公告）日：2005-11-17

  A compound of the formula (I) is described where: R 1 is a) H b) a straight-chain or branched alkyl radical having from 1 to 16 carbon atoms or a straight-chain or branched alkenyl radical having from 2 to 16 carbon atoms, in which b1) one or more nonadjacent and nonterminal CH 2 groups may be replaced by —O—, —C(═O)O—, —O—C(═O)—, —O—C(═O)—O—, —C(═O)— or —Si(CH 3 ) 2 — and/or b2) one CH 2 group may be replaced by —C≡C—, cyclopropane-1,2-diyl, cyclobutane-1,3-diyl, cyclohexane-1,4-diyl or phenylene-1,4-diyl and/or b3) one or more hydrogen atoms may be replaced by F and/or Cl c) -M 1 -A 1 -R 5 R 2 has the same possible definitions as specified for R 1 , with the exception of H, but independently of the definition of R 1 and R 5 R 5 has the same possible definitions as specified for R 1 , with the exception of -M 1 -A 1 -R 5 , but independently of the definition of R 1 and R 3 M 1 is —CO—O—, —O—CO—, —CH 2 —O—, —O—CH 2 —, —CF 2 —O—, —O—CF 2 —, —CH═CH—, —CF═CF—, —C≡C—, —CH 2 —CH 2 —CO—O—, —O—CO—CH 2 —CH 2 —, —CH 2 —CH 2 —, —CF 2 —CF 2 —, —(CH 2 ) 4 —, —OC(═O)CF═CF— or a single bond A 1 is 1,4-phenylene in which one or two hydrogen atoms may be replaced by F, Cl, CN and/or OCF 3 or three hydrogen atoms may be replaced by fluorine, 1,4-cyclohexylene in which one or two hydrogen atoms may be replaced by CH 3 and/or F, 1-cyclohexene-1,4-diyl in which one hydrogen atom may be replaced by CH 3 or F, pyrimidine-2,5-diyl, pyridine-2,5-diyl in which one hydrogen atom may be replaced by F, or 1,3-dioxane-2,5-diyl p, q, rare each independently 0 or 1, i.e. at the value zero, —H is present at the appropriate position instead of —F, with the proviso that: at least one of p, q, r is 1.

  描述了一种式子为（I）的化合物，其中：R1为a）H，b）具有1至16个碳原子的直链或支链烷基基团或具有2至16个碳原子的直链或支链烯基基团，在其中b1）一个或多个非相邻和非端部的CH2基团可以被替换为—O—、—C（═O）O—、—O—C（═O）—、—O—C（═O）—O—、—C（═O）—或—Si（CH3）2—和/或b2）一个CH2基团可以被替换为—C≡C—、环丙烷-1,2-二基、环丁烷-1,3-二基、环己烷-1,4-二基或苯-1,4-二基和/或b3）一个或多个氢原子可以被F和/或Cl替换c）-M1-A1-R5R2具有与R1指定的相同可能的定义，除了H之外，但与R1和R5R5定义的独立定义，除了-M1-A1-R5之外，但与R1的定义无关，R3M1为—CO—O—、—O—CO—、—CH2—O—、—O—CH2—、—CF2—O—、—O—CF2—、—CH═CH—、—CF═CF—、—C≡C—、—CH2—CH2—CO—O—、—O—CO—CH2—CH2—、—CH2—CH2—、—CF2—CF2—、—（CH2）4—、—OC（═O）CF═CF—或单键A1为1,4-苯基，其中一个或两个氢原子可以被F、Cl、CN和/或OCF3替换或三个氢原子可以被氟替换，1,4-环己基，其中一个或两个氢原子可以被CH3和/或F替换，1-环己烯-1,4-二基，其中一个氢原子可以被CH3或F替换，嘧啶-2,5-二基，吡啶-2,5-二基，其中一个氢原子可以被F替换，或1,3-二氧杂环戊烷-2,5-二基p、q、r各自独立为0或1，即在值为零时，在适当位置存在—H而不是—F，但须满足：p、q、r中至少有一个为1。
• [EN] MODULATORS OF SEROTONIN RECEPTORS<br/>[FR] MODULATEURS DES RECEPTEURS DE LA SEROTONINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005035533A1

  公开（公告）日：2005-04-21

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impared glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂、含有这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病症和疾患的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑症、抑郁症、强迫症、惊恐症、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；以及使用这些化合物和组合物治疗胃肠道疾病。
• MODULATORS OF SEROTONIN RECEPTORS
  申请人：Wacker A. Dean

  公开号：US20070213337A1

  公开（公告）日：2007-09-13

  The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.

  本发明提供了5-羟色胺受体调节剂，包含这种调节剂的药物组合物以及使用这些化合物和组合物治疗与5-羟色胺受体调节相关的各种疾病、病况和障碍的方法，例如：代谢性疾病，包括但不限于肥胖症、糖尿病、糖尿病并发症、动脉粥样硬化、糖耐量受损和血脂异常；中枢神经系统疾病，包括但不限于焦虑、抑郁、强迫症、惊恐障碍、精神病、精神分裂症、睡眠障碍、性功能障碍和社交恐惧症；头痛；偏头痛；和使用这些化合物和组合物治疗胃肠道疾病。